26 results
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
9 May 24
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
4:10pm
designation from the European Medicines Agency and the Innovation Passport from the United Kingdom’s Medicines and Healthcare Products Regulatory
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
the European Medicines Agency and the Innovation Passport from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency
8-K
EX-99.1
zh3wm
9 Nov 23
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4:07pm
8-K
EX-99.1
bs4n6a
10 Aug 23
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
4:09pm
8-K
EX-99.1
7hu5ewdq
11 May 23
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
4:10pm
PRRN14A
ynhw377tx7jsk5pph
13 Apr 21
Revised preliminary proxy statement filed by non-management
4:16pm
PREC14A
2rsg76cd
7 Apr 21
Preliminary proxy with contested solicitation
5:48pm
DFAN14A
EX-99.1
cfxg4mlli
18 Mar 21
Additional proxy materials by non-management
2:28pm
DEFA14A
can5znspvd d28
17 Mar 21
Additional proxy soliciting materials
5:28pm